Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.91 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.91 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.91 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.91 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.91 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.91 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.91 |
| ▸ | HTR3B | O95264 | 1/20 | 0.91 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.91 |
| ▸ | CHRNG | P07510 | 1/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.91 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.91 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.91 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613093 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL5293891 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL1721244 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802478 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802481 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802707 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| Bromide SCHEMBL7331542 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802708 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802483 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| (+/-)Nicotine SCHEMBL797620 | 0.95 | ALDH1A1 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023036691-A1 | MODULATING ALKALOID PROFILES IN NICOTIANA TABACUM | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-03-16 | — | — | WO | disclosed |
| EP-3972584-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | Poviva Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-10682359-B2 | Inhibitors of glucose kinases, along with methods of their formation and use | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-06-16 | — | — | US | disclosed |
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-8609708-B2 | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-12-17 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100298345-A1 | SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298345-A1 | SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298345-A1 | SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-08-07 | — | — | US | disclosed |
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-08-07 | — | — | US | disclosed |
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-08-07 | — | — | US | disclosed |
| WO-2005066162-A1 | SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2005-07-21 | — | — | WO | disclosed |
| US-5741802-A | FOR TREATMENT OF MEMORY LOSS | UNIVERSITY OF FLORIDA (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0659078-A4 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM. | UNIV FLORIDA (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0659078-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005288-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | CYP2A13, CYP2A6, CYP2B6 | CHRNB2 22/4885CHRNA7 37/4885CHRNA4 15/4885 |
| US-20100298345-A1 | SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER | CYP2A13, CYP2A6, CYP2B6 | CHRNB2 22/4885CHRNA7 37/4885CHRNA4 15/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | CHRNB2 871/4885CHRNA7 641/4885CHRNA4 869/4885 |
| US-10682359-B2 | Inhibitors of glucose kinases, along with methods of their formation and use | GCK, GCKR, GALK1 | CHRNB2 3000/4885CHRNA7 2740/4885CHRNA4 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.